Studying Genes in Women With Hepatitis C Virus, Hepatitis B Virus, Human Papillomavirus, and/or HIV Infection
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Studying the genes expressed in samples of blood from women with hepatitis C virus, hepatitis B virus, human papillomavirus, and/or HIV infection may help doctors identify biomarkers related to infections and cancer.
PURPOSE: This research study is looking at genes in women with hepatitis C virus, hepatitis B virus, human papillomavirus, and/or HIV infection.
Condition | Intervention |
---|---|
Liver Cancer Nonneoplastic Condition Precancerous Condition |
Genetic: genetic linkage analysis Genetic: molecular genetic technique Genetic: polymerase chain reaction Other: laboratory biomarker analysis |
Study Type: | Observational |
Official Title: | HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS) |
- Infection [ Designated as safety issue: No ]
Estimated Enrollment: | 3500 |
Study Start Date: | August 2002 |
Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- Examine the role of HLA and killer immunoglobulin-like receptors (KIR) in the natural history of human papillomavirus (HPV), hepatitis C virus (HCV), and hepatitis B virus (HBV) in HIV-positive and HIV-negative women.
- Test the hypothesis that KIR and HLA genotype may play a role in the pathogenesis of HIV, HPV, HCV, and HBV infection.
- Determine the relationship between KIR and HLA genes and risk of HIV infection, according to likely source of virus exposure (sexual versus IV) and demographic factors such as race.
- Determine the relationship between KIR and HLA genes and CD4+ cell counts and serum HIV RNA levels.
- Determine the relationship between KIR and HLA genes and incidence of AIDS and other clinical endpoints, including AIDS-associated malignancies and opportunistic infections.
- Determine the relationship between KIR and HLA genes and the response to highly active antiretroviral treatment (HAART), as measured by increases in CD4+ T-cell levels, reduction in serum HIV RNA levels, and reduction in AIDS rates.
- Determine the relationship between KIR and HLA genes and risk of HCV infection among injecting drug users, according to viral subtype and demographic factors, such as race.
- Determine the relationship between KIR and HLA genes and persistence of HCV infection.
- Determine the relationship between KIR and HLA genes and incidence of HCV-related end-stage liver disease and/or hepatocellular carcinoma.
- Determine the relationship between KIR and HLA genes and response to immunotherapy, as measured by viral load and liver function tests.
- Determine the relationship between KIR and HLA genes and the natural history of HPV and cervical dysplasia in HIV-positive and HIV-negative women.
- Determine the relationship between KIR and HLA genes and persistence of HBV infection.
- Determine the relationship between KIR and HLA genes and incidence of HBV-related end-stage liver disease and/or hepatocellular carcinoma.
OUTLINE: This is a multicenter study.
Blood samples are analyzed for genomic DNA isolated from lymphoblastoid B-cell lines or from peripheral blood lymphocytes and used for genotyping of HLA and killer immunoglobulin-like receptors (KIR) genes. High-resolution HLA class I and class II genotyping is performed using the HLA class I genes (HLA-A, -B, -C), which are amplified using polymerase chain reaction (PCR) and sequenced.
Previously collected clinical data is also evaluated. Patients were followed every 6 months on the Women's Interagency HIV Study and underwent physical and gynecological examinations and completed questionnaires. Blood samples, cervical lavage specimens, and cervical cytology samples were also collected at that time.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
DNA and relevant clinical data from properly consented Women's Interagency HIV Study (WIHS) subjects meeting 1 of the following criteria:
- HIV positive
- HIV negative but at high risk of HIV infection
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
United States, Maryland | |
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | |
Bethesda, Maryland, United States, 20892-1182 |
Principal Investigator: | Stephen J. O'Brien | National Cancer Institute - Frederick |
Additional Information:
No publications provided
ClinicalTrials.gov Identifier: | NCT00897689 History of Changes |
Other Study ID Numbers: | CDR0000594251, NCI-02-C-N253 |
Study First Received: | May 9, 2009 |
Last Updated: | September 4, 2010 |
Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
adult primary liver cancer adult primary hepatocellular carcinoma high-grade squamous intraepithelial lesion low-grade squamous intraepithelial lesion |
HIV infection human papilloma virus infection hepatitis B infection hepatitis C infection |
Additional relevant MeSH terms:
HIV Infections Hepatitis Hepatitis A Hepatitis B Hepatitis C Liver Neoplasms Precancerous Conditions Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Immunologic Deficiency Syndromes Immune System Diseases Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Enterovirus Infections Picornaviridae Infections Hepadnaviridae Infections DNA Virus Infections Flaviviridae Infections Digestive System Neoplasms Neoplasms by Site Neoplasms |
ClinicalTrials.gov processed this record on February 26, 2013